skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Gene expression overlap affects karyotype prediction in pediatric acute lymphoblastic leukemia

Journal Article · · Leukemia
 [1];  [2];  [2];  [1];  [3];  [3];  [4];  [4];  [4];  [4];  [4];  [2];  [2];  [2];  [2];  [2];  [2];  [4];  [5];  [6] more »;  [7];  [2] « less
  1. Sandia National Lab. (SNL-NM), Albuquerque, NM (United States). Computational Biology
  2. Univ. of New Mexico, Albuquerque, NM (United States). School of Medicine. Dept. of Pathology. Cancer Research and Treatment Center
  3. Univ. of New Mexico, Albuquerque, NM (United States). School of Medicine. Dept. of Pathology. Cancer Research and Treatment Center. Dept. of Computer Science, Mathematics and Statistics, Physics and Astronomy. Center for High Performance Computing
  4. Univ. of New Mexico, Albuquerque, NM (United States). Dept. of Computer Science, Mathematics and Statistics, Physics and Astronomy. Center for High Performance Computing
  5. Univ. of Florida, Gainesville, FL (United States). General Clinical Research Center
  6. Univ. of Alabama, Birmingham, AL (United States). Dept. of Genetics
  7. Medical College of Wisconsin, Milwaukee, WI (United States). Dept. of Pediatrics. Midwest Children’s Cancer Center
+ Show Author Affiliations

Leukemia is the most common childhood malignancy in the United States. Acute lymphoblastic leukemia (ALL) accounts for 75% of new leukemia cases in children. Although the outcome for children with ALL has improved dramatically over the past three decades, 25% of children with ALL still develop recurrent disease. Current risk classification schemes in pediatric ALL use clinical and laboratory parameters such as age and initial white blood cell count, as well as the presence of specific ALL-associated cytogenetic or molecular genetic abnormalities. Stratification based on cytogenetic analysis and molecular genetic detection consider B precursor ALL translocations such as t(12;21)(TEL-AML1), t(1;19)(E2A-PBX1) and t(9;22)(BCR-ABL), as well as numerical imbalances such as hyperdiploidy, specific chromosome trisomies or hypodiploidy. Despite such efforts, current diagnosis and risk classification schemes in pediatric ALL remain imprecise. In particular, it is likely that a significant number of higher-risk children are currently overtreated and could be cured with less intensive regimens, resulting in fewer toxicities and long-term side effects. Finally and conversely, a significant number of children in lower-risk categories still relapse and precise means to prospectively identify them have remained elusive.

Research Organization:
Sandia National Lab. (SNL-NM), Albuquerque, NM (United States); Univ. of New Mexico, Albuquerque, NM (United States)
Sponsoring Organization:
USDOE; SNL Laboratory Directed Research and Development (LDRD) Program; National Inst. of Health (NIH) (United States); The Leukemia and Lymphoma Society (United States)
Grant/Contract Number:
AC04-94AL85000; NCI CA88361; NCI CA114762
OSTI ID:
1426985
Report Number(s):
SAND2007-0699J; 524123
Journal Information:
Leukemia, Vol. 21, Issue 6; ISSN 0887-6924
Publisher:
Nature Publishing Group (NPG)Copyright Statement
Country of Publication:
United States
Language:
English
Citation Metrics:
Cited by: 7 works
Citation information provided by
Web of Science

References (7)

Classification of pediatric acute lymphoblastic leukemia by gene expression profiling journal October 2003
Acute Lymphoblastic Leukemia journal April 2004
A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial journal July 2001
A Bayesian Network Classification Methodology for Gene Expression Data journal August 2004
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling journal March 2002
Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. journal January 1998
Intensification With Intermediate-Dose Intravenous Methotrexate Is Effective Therapy for Children With Lower-Risk B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study journal March 2000

Cited By (1)

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia journal February 2010

Similar Records

A molecular cytogenetic study of imprinting effect in childhood acute lymphoblastic leukemia with the t(1;19)(q23;p13)
Journal Article · Thu Sep 01 00:00:00 EDT 1994 · American Journal of Human Genetics · OSTI ID:1426985
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
Journal Article · Tue May 23 00:00:00 EDT 1995 · Proceedings of the National Academy of Sciences of the United States of America · OSTI ID:1426985
+7 more
Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases
Journal Article · Tue Oct 10 00:00:00 EDT 1995 · Genomics · OSTI ID:1426985

Related Subjects

60 APPLIED LIFE SCIENCES
59 BASIC BIOLOGICAL SCIENCES